Telix Completes Japan Phase 3 Enrollment for Illuccix

Telix completes Japan Phase 3 enrollment for Illuccix

MELBOURNE, Australia and TOKYO, July 17, 2026 /PRNewswire/ -- Telix Pharmaceuticals (ASX: TLX, NASDAQ: TLX, "Telix") today announced completion of patient enrollment in the pivotal Phase 3 registration study of TLX591-Px (Illuccix®, Kit for the preparation of 68Ga-PSMA-11[1]) for prostate cancer imaging in Japanese patients. Illuccix Japan[2] is a Phase 3 prospective, open-label, multicenter study designed to evaluate the detection efficacy and …

Telix Completes Patient Enrollment in TLX591-Px (Illuccix®) Japan Phase 3 Study

Telix Completes Patient Enrollment in TLX591-Px (Illuccix®) Japan Phase 3 Study Melbourne (Australia) and Tokyo (Japan) | July 17, 2026 Completed enrollment of 105 patients in Phase 3 registration study of TLX591-Px (Illuccix®) for prostate cancer imaging in Japan. The study data will be used to support a New Drug Application (NDA) for TLX591-Px in Japan. Telix today announced completion of patient enrollment in the pivotal Phase 3 registrat…